Amarin | AMRN - Cost Of Sales

Stock Price
13.98
Daily Change
-0.15 -1.03%
Monthly
-7.27%
Yearly
28.94%
Q1 Forecast
15.11

Amarin reported $16.89M in Cost of Sales for its fiscal quarter ending in March of 2025.





Cost Of Sales Change Date
AbbVie USD 4.55B 757M Dec/2025
Alnylam Pharmaceuticals USD 267.72M 67.57M Dec/2025
Amarin USD 16.89M 18.51M Mar/2025
AstraZeneca USD 3.27B 471M Dec/2025
BioCryst Pharmaceuticals USD 12.27M 9.04M Dec/2024
Esperion Therapeutics USD 51.63M 22.2M Sep/2024
GlaxoSmithKline GBP 2.61B 377M Dec/2025
Halozyme Therapeutics USD 102.15M 29.14M Dec/2025
Heron Therapeutics USD 9.46M 1.61M Sep/2024
Ionis Pharmaceuticals USD 8M 5.66M Dec/2025
Nektar Therapeutics USD 4.43M 5.3M Sep/2024
Neurocrine Biosciences USD 17.6M 246.4M Dec/2025
Novartis USD 3.54B 217M Sep/2025